Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its rarity, we will encounter them. While CUPs manifest a wide variety of clinical presentations, they have often resulted in poor prognosis. Although platinum/taxane combination chemotherapy, e.g. carbo...

Full description

Bibliographic Details
Main Authors: Hirotoshi Yasui, Kazuhide Sato, Yoshihiro Takeyama, Toshio Kato, Hiroyuki Hashimoto, Yasutaka Fukui, Nagashima Yoshihisa, Matsuyoshi Maeda, Hideo Gonda, Ryujiro Suzuki
Format: Article
Language:English
Published: Karger Publishers 2014-08-01
Series:Case Reports in Oncology
Subjects:
Carcinoma of unknown primary site
Bronchoscopy
Immunohistochemistry
Carboplatin + paclitaxel + bevacizumab + erlotinib
Maintenance chemotherapy
Online Access:http://www.karger.com/Article/FullText/366268

Internet

http://www.karger.com/Article/FullText/366268

Similar Items